Medscape1d
Fat Loss vs Weight Loss: Helping GLP-1 Patients Focus on the Right Measurement
To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...
Physician's Weekly5d
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Managed Healthcare Executive5d
GLP-1 Receptor Agonists Offer Less Invasive Alternative to Bariatric Surgery for CV Health in Obese Patients | ACC 2025
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
Mirage News3d
US Adults Boost Spending on GLP-1 Receptor Agonists
Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...
Medscape3d
Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes
As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation ... receiving any of these LA GLP1-RAs. However, there are several ongoing trials ...
clinicaltrialsarena6d
ACC 25: GLP-1 receptor agonists emerge for treating atrial fibrillation
investigating the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the incidence of atrial fibrillation (AF) following hospitalisation for heart failure (HF) were released. The ...
EurekAlert!4d
Spending on glucagon-like peptide-1 receptor agonists among US adults
Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...